A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) f...

Descripción completa

Detalles Bibliográficos
Autores principales: Doustmohammadian, Azam, Nezhadisalami, Ahmad, Safarnezhad Tameshke, Fahimeh, Motamed, Nima, Maadi, Mansooreh, Farahmand, Mohammad, Sohrabi, Masoudreza, Clark, Cain C. T., Ajdarkosh, Hossein, Faraji, Amir Hossein, Nikkhah, Mehdi, Sobhrakhshankhah, Elham, Ebrahimi, Ramin, Zamani, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365981/
https://www.ncbi.nlm.nih.gov/pubmed/35966875
http://dx.doi.org/10.3389/fmed.2022.937554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365981/
https://www.ncbi.nlm.nih.gov/pubmed/35966875
http://dx.doi.org/10.3389/fmed.2022.937554

Ejemplares similares